| Name | Title | Contact Details |
|---|---|---|
Karen Stringer |
VP, Assistant General Counsel, Deputy Chief Compliance Officer | Profile |
Kristen Galloway |
Vice President and Assistant General Counsel | Profile |
Kristen Greene |
Vice President and Assistant General Counsel | Profile |
Danielle Bello |
Counsel and Director Litigation, Risk and Claims | Profile |
Megan Isaacson |
Associate Director, Legal Operations | Profile |
Advanced Targeting Systems is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Verséa Health is a diversified global healthcare company engaged in scientific discovery, development and commercialization of innovative products and services intended to diagnose, manage, and treat debilitating diseases.
physIQ is the leader in digital medicine, dedicated to generating unprecedented health insight using continuous wearable biosensor data and advanced analytics. Its industry-leading, enterprise-ready cloud platform continuously collects and processes data from wearable biosensor using a deep portfolio of FDA-cleared analytics. The company has published one of the most rigorous clinical studies to date in digital medicine and are pioneers in developing, validating, and achieving regulatory approval of Artificial Intelligence-based analytics. With applications in both clinical trial support and healthcare, physIQ is transforming continuous physiological data into insight for health systems, payers, and pharmaceutical companies
TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.